Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma

International Journal of Pancreatology

Volumn 24, Issue 3, 1998, Pages 169-180

  Fisher, William E ^a,b   Muscarella, Peter ^c   Boros, Laszlo G ^c   Schirmer, William J ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Gastrointestinal hormones; Pancreatic adenocarcinoma

Indexed keywords

BOMBESIN; CHOLECYSTOKININ; EPIDERMAL GROWTH FACTOR; GASTRIN; GASTROINTESTINAL HORMONE; INSULIN; PANCREAS POLYPEPTIDE; PANCREASTATIN; SECRETIN; SOMATOMEDIN C; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION;

ADENOCARCINOMA; ANIMALS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL HORMONES; GROWTH INHIBITORS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032408106     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mammal: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104-107.
2. Huggins, C. Endocrine-induced regression of cancers, in Nobel Lectures in Physiology - Medicine 1963-1970. Elsevier, Amsterdam; 1972.
3. Hubay CA, Arafah B, Gordon NH, Guyton SP, Crowe JP. Hormone receptors. An update and application. Surg Clin North Am 1984; 64: 1155.
4. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma: a review of clinical observations. Acta Obstet Gynecol Scand 1984; 63: 441.
5. Morisset J, Genki P, Lord A, Solomon TE. Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept 1982; 4: 49.
6. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Vaysse N, Susini C. Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Metabolism 1996; 45(8, Suppl. 1): 14-16.
7. Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose somatostatin analog RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 1991; 51: 5980-5986.
8. Meijers M, Woutersen RA, Van Garderen-Hoetmer A, Baker GH, DeJong FH, Foekens JA, Klijn JGM. Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters. Int J Cancer 1992; 50: 246-251.
9. Paz-Bouza JI, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1987; 84: 1112-1116.
10. Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 1984; 81: 248-252.
11. Zalatnai A, Schally AV. Treatment of N-Nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160. Cancer Res 1989; 49: 1810-1815.
12. Szepeshazi K, Lapis K, Schally AV. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer 1991; 49: 260-266.
13. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 1989; 4(5): 521-528.
14. Srkalovic G, Ren-Zhi C, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 1990; 70(3): 661-669.
15. Liebow C, Hierowski M, DuSapin K. Hormonal control of pancreatic cancer growth. Pancreas 1986; 1(1): 44-48.
16. Liebow C, Reilly C, Serano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86: 2003-2007.
17. Takeda Y, Escribano MJ. Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines. J Cancer Res Clin Oncol 1991; 117: 416-420.
18. Weckbecker G, Liu R, Tolesvai L. Inhibitory effect of the somatostatin analog octreotide (SMS-201-995) on the growth of human and animal tumors in rodent models. Contrib Oncol 1992; 42: 362-369.
19. Radulovic S, Comaru-Schally AM, Milovanovic S, Schally A. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas 1993; 8(1): 88-97.
20. Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett 1992; 62: 263-271.
21. Gillespie J, Poston GJ, Schachter M, Guillou PJ. Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer 1992; 66(3): 483-487.
22. Poston GJ, Townsend CM, Rajararnan S, Thompson JC, Singh P. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 1990; 5(2): 151-157.
23. Singh P. Townsend CM, Poston GJ, Reubi JC. Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts. J Steroid Biochem Mol Biol 1991; 39(5A): 759-767.
24. Upp JR, Olson D, Poston GJ, et al. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg 1988; 155: 29-35.
25. Klijn JGM, Hoff AM, Th AS, Planting J, Verweij T, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62(4): 627-630.
26. Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 1992; 69(3): 648-650.
27. Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 1992; 164: 348-353.
28. Fisher WE, Boros LG, Tamaddon AK, O'Dorisio MS, O'Dorisio TM, and Schirmer WJ. Somatostatin-receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo. Surg Forum 1995; 46: 137-140.
29. Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 1996; 120: 234-241.
30. Estival A, Mounielou P, Trocheris V, Scemama JL, Slemente F, Hollande E, Ribet A. Presence of VIP receptors in a human pancreatic adenocarcinonia cell line: modulation of the cAMP response during cell proliferation. Biochem Biophys Res Commun 1983; 111: 958-963.
31. Ruellan C, Scemama JL, Clerc P, Fagot-Revurat P, Clemente F, Ribet A. VIP regulation of a human pancreatic cancer cell line: Capan-1. Peptides 1986; 7(1): 267-271.
32. Poston GJ, Yao CZ, Upp JR, Alexander RW, Townsend CM, Thompson JC. Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. Pancreas 1988; 3(4): 439-443.
33. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
34. Hazelwood RL, Biosynthesis, chemistry and storage of islet (endocrine) products, in The Endocrine Pancreas, Hadley ME, ed. Prentice Hall, Englewood Cliffs, NJ; 1989, Chap. 3.
35. Grossman MI, Brown JC, Said S, et al. Candidate hormones of the gut. Gastroenterology 1974; 67: 730-755.
36. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417,418.
37. Liu CD, Balasubramaniam A, Saxton RE, Piava M, McFadden DW. Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1. J Surg Res 1995; 58: 707-712.
38. Liu CD, Slice LW, Balasubramaniam A, Walsh JH, Newton TR, Saxton RE, McFadden DW. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 1995; 118: 229-236.
39. Ramo OJ, Balasubramaniam A, Sheriff S, Rogers DH, McCullough PJ, Bell RH. Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma. Neuropeptides 1990; 15: 101-106.
40. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-478.
41. Efendic S, Tatemoto K, Mutt V, Quan C, Chang D, Ostenson CG. Pancreastatin and islet hormone release. Proc Natl Acad Sci USA 1987; 84: 7257-7260.
42. Funakoshi A, Miyaska K, Nakamura R, Kitani K, Tatemoto K. Inhibitory effect of pancreastatin on pancreatic exocrine secretion in the conscious rat. Reg Peptides 1989; 25: 157-66.
43. Smith JP, Kramer S, Bagheri S. Effects of pancreastatin (24-49) on growth of normal pancreas and pancreatic cancer. Pancreas 1991; 6(5): 551-557.
44. Mainz DL, Black O, Webster PD. Hormonal control of pancreatic growth. J Clin Invest 1973; 52: 2300-2304.
45. Pour PM, Lawson T, Helgeson S, Donnelly T, Stepan K. Effect of cholecystokinin on pancreatic carcinogenesis in the hamster model. Carcinogenesis 1988; 9(4): 597-601.
46. Johnson FE, LaRegina MC, Martin SA, Bashiti HM. Cholecystokinin inhibits pancreatic carcinogenesis. Cancer Detect Prevent 1983; 6: 389-402.
47. Howatson AC, Carter DC. Pancreatic carcinogenesis enhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer 1985; 51: 107-114.
48. Andren-Sandberg A, Dawiskiba S, Ihse I. Studies of the effect of caerulein administration on experimental pancreatic carcinogenesis. Scand J Gastroenterol 1984; 19: 122-128.
49. Corra S, Kazakoff K, Lawson RA, Adrian TE, Pour PM. Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis(2-oxopropyl)amine (BOP) in hamster pancreas. Cancer Lett 1992; 62: 251-256.
50. Appel MJ, Meijers M, Van Garderen-Hoetmer A, Lamers CBHW, Rovati LC, et al. Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats. Br J Cancer 1992; 66: 46-50.
51. Townsend CM, Franklin RB, Watson LC, Glass EJ, Thompson JC. Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 1981; 32: 228,229.
52. Shivaram S, Crist KA, Chaudhuri B, Mucci SJ, Chaudhuri PK. Effect of CCK receptor antagonist on growth of pancreatic adenocarcinoma. J Surg Res 1992; 53: 234-237.
53. Karsenty L, Hajri A, Aprahamian M, Garaud JC, Doffoel M, Damge C. Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8. Pancreas 1993; 8(2): 204-211.
54. Bell RH, Kuhlmann ET, Jensen RT, Longnecker DS. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. Cancer Res 1992; 52: 3295-3299.
55. Smith JP, Kramer S, Solomon TE. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept 1991; 32: 341-349.
56. Smith JP, Rickabaugh CA, McLaughlin PJ, Zagon IS. Cholecystokinin receptors and Panc-1 human pancreatic cancer cells. Am J Physiol 1993; 265(28): G149-G155.
57. Hudd C, LaRegina MC, Devine JE, Palmer DC, Herbold DR, Beinfeld MC, et al. Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice. Am J Surg 1989; 157: 386-394.
58. Upp JR Jr, Singh P, Townsend CM, Thompson JC, Thompson P. Predicting response to endocrine therapy in human pancreatic cancer with cholecystokinin receptors. Gastroenterology 1987; 92: 1677 (abstract).
59. Alexander RW, Upp JR Jr, Singh P, Hugh T, Poston GJ, Townsend CM Jr, Thompson JC. Asperlicin inhibits the growth of a xenografted human pancreatic carcinoma. Gastroenterology 1987; 92: 1293 (abstract).
60. Funakoshi A, Kono A. Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice. Gastroenterologia Japonica 1992; 27(1): 78-82.
61. Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990; 35(11): 1377-1384.
62. Smith JP, Kramer S, Bagheri S. Effects of a high-fat diet and S364-718 on growth of human pancreas cancer. Dig Dis Sci 1990; 35(6): 726-732.
63. Pinho E, Jamshidipour R, Moossa AR, Howell SB. Synergistic enhancement of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in pancreatic cancer (meeting abstract). Proc Ann Meet Am Assoc Cancer Res 1992; 33: A3297.
64. Maani R, Townsend CM Jr, Gomez G, Thompson JC, Singh R. A potent CCK receptor antagonist (MK-329) inhibits the growth of human pancreatic cancer in nude mice. Gastroenterology 1988; 94: A274 (abstract).
65. Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R, Berlin R, Levin B. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992; 7(2): 165-171.
66. Steffensrud S, Erichsen H, Roysland P, Halvorsen TB, Klepp R, Klepp O, Wunsch E, Petersen H. Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. Scand J Gastroenterol 1984; 19: 909-915.
67. Douglas BR, Woutersen RA, Jansen JBMJ, Rovati LC, Lamers CBHW. Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters. Eur J Pharmacol 1989; 161: 209-214.
68. Meijers M, Appel MJ, Van Garderen-Hoetmer A, Lamers CBHW, Rovati LC, Jansen JBMJ, Woutersen RA. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumors in rats: modulation by the cholecystokinin receptor antagonist lorglumide. Carcinogenesis 1992; 13(9): 1525-1528.
69. Douglas BR, Woutersen RA, Jansen JBMJ, DeJong AJL, Rovati LC, Lamers CBHW. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 1989; 96: 462-469.
70. Hajri A, Balboni G, Koenig M, Garaud JC, Damge C. Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res 1992; 52: 3726-3732.
71. Meijers M, Van Garderen-Hoetmer A, Lamers CB, Rovati LC, Jansen JB, Woutersen RA. Effects of bombesin on the development of N-Nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. Cancer Lett 1991; 59(1): 45-50.
72. Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B. Inhibitory effect of bombesin/ gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 1991; 51: 5980-5986.
73. Szepeshazi K, Schally AV, Groot K, Halmos G. Effect of bombesin, gastrin-releasing peptide (GRP) (14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 1993; 54(2): 282-289.
74. Alexander RW, Upp JR, Poston GJ, Townsend CM Jr, Singh P, Thompson JC. Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas 1988; 3(3): 297-302.
75. Harper AA, Scratcherd T. Physiology, in The Exocrine Pancreas, Howat HT, Sarles H, eds. Saunders, Philadelphia 1979; pp. 50-85.
76. Howatson AG, Carter DC. Pancreatic carcinogenesis: effect of secretin in the hamster-nitrosamine model. J Natl Cancer Inst 1987; 78: 101-105.
77. Pour PM, Kazakoff K. Effect of secretin on pancreatic carcinogenesis in the hamster model. Cancer Lett 1989; 46: 57-62.
78. Estival A, Clemente F, Ribet A. Adenocarcinoma of the human exocrine pancreas: presence of secretin and caerulein receptors. Biochem Biophys Res Commun 1981; 102(4): 1336-1341.
79. Watson SA, Crosbee DM, Morris DL, Robertson JFR, Makovec F, Rovati LC, Hardcastle JD. Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumor cell growth. Br J Cancer 1992; 65: 879-883.
80. Dembinsky A, Gregory H, Konturek SJ, Waterfield MD. Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosu in rats. J Physiol 1982; 325: 35-42.
81. Korc M, Matrisian LM, Plank SR, Magun BM. Binding of epidermal growth factor in rat pancreatic acini. Biochem Biophys Res Commun 1983; 111: 1066-1073.
82. Chester JF, Gaissert HA, Ross JS, Malt RA. Pancreatic cancer in the Syrian hamster induced by N-Nitrosobis(2-oxopropyl)-amine: cocarcinogenic effect of epidermal growth factor. Cancer Res 1986; 46: 2954-2957.
83. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986; 83: 5141-5144.
84. Massague J. Epidermal growth factor-like transforming growth factor-II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J Biol Chem 1983; 258: 13,614-13,620.
85. Smith JJ, Derynck R, Korc M. Production of transforming growth factor a in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 1987; 84: 7567-7570.
86. Takeda Y, Escribano MJ. Effects of insulin and somatostatin on the growth and colony formation of two human pancreatic cancer cell lines. J Cancer Res Clin Oncol 1991; 117: 416-420.
87. Fisher WE, Boros LG, Schiemer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 1996; 63(1): 310-313.
88. Ohmura E, Okada M, Onoda N, Kamiya Y, Marakami H, Tsushima T, Shizume K. Insulin-like growth factor I and transforming growth factor-a as autocrine growth factor in human pancreatic cancer cell growth. Cancer Res 1990; 50: 103-107.